Smaller Default Larger

A multi-site prospective study of all non-O blood group patients for whom IVIG has been prescribed at a cumulative dose of equal to or greater than 2 g/kg within a 28-day period (adjusted for ideal body weight) will be performed. Case report forms documenting previous medical history, IVIG treatments and adverse reactions, and concurrent medication use will be collected. Laboratory testing for hemolysis will be performed at baseline, immediately following the completed high-dose cycle (usually administered over 1-2 days), and then again at 5-10 days post-infusion. IVIG associated hemolysis will be defined and graded as per the criteria of the Canadian IVIG Pharmacovigilance Group.